BioActor joins Solabia Group
Solabia Group acquires BioActor to boost growth and strengthen its presence in the nutraceuticals market
BioActor: a new strategic acquisition for the Solabia group in the Nutrition Sector
Solabia, a major player in the nutrition market, has acquired a majority stake in BioActor, a leader in the development and marketing of clinically proven natural health ingredients used by top supplement brands. Founded in 2011 and based on the Maastricht Health Campus, BioActor pioneers the development and commercialization of clinically evaluated polyphenols extracted from plants and edible fruits, serving the world’s leading supplement brands.
Exceptional Quality Health Ingredients Backed by In-House Clinical Research
With an outstanding in-house clinical research team and direct access to leading research centers, BioActor ensures the highest quality of health ingredients. This empowers supplement brands to deliver exceptional solutions and stand out with high-performance, healthy products. Choosing BioActor means choosing quality for long-lasting and satisfying results. Currently, BioActor exports to over 20 countries worldwide, catering to major brands in the nutrition and supplements sectors.
Strengthening Solabia’s Nutrition Division with a Broader Range of Ingredients
Solabia already excels in the nutrition sector, offering original ingredients recognized for their health benefits, including Algatech’s active ingredients derived from microalgae. This strategic investment will enable Solabia to leverage BioActor’s broader range of ingredients and expertise, fortifying its nutrition division’s position in the rapidly growing market. As customers increasingly seek high-quality, natural, and clinically-proven ingredients,
The CEO of Solabia, Jean-Baptiste Dellon, stated that he is highly impressed by BioActor’s dynamic team and innovation, and is delighted to welcome them into Solabia. He also expressed his eagerness to collaborate with BioActor to enhance the growth of the current product portfolio and accelerate the development of new ingredients.
Hans van der Saag, founder and CEO of BioActor, will maintain a minority stake and remain as CEO of Bioactor. He expressed his satisfaction with the acquisition of his company by Solabia, considering it a crucial step for BioActor and its team in achieving their mission of delivering clinically evaluated and naturally sourced health ingredients to global consumers.
He looks forward to continuing the collaboration with Solabia to enhance current product offerings and introduce new ingredients.